1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Verastem RAMPS Up In Rare Ovarian Cancer With Avutometinib/Defactinib Filing

Data Announced In Pancreatic Cancer

 
• By Alaric DeArment

The company announced topline data from the RAMP 201 trial in low-grade serous ovarian cancer, a rare disease with no FDA-approved treatments, and started a rolling FDA submission.

• Source: Shutterstock

Verastem, Inc. is plowing ahead with its combination of the RAF/MEK inhibitor avutometinib and the FAK inhibitor defactinib in solid tumors, announcing topline data and the start of a rolling regulatory submission for the two drugs in a rare form of ovarian cancer and interim data for the combination in pancreatic cancer.

The company held a call with analysts 24 May to discuss the recent data from the Phase II RAMP 201 study of avutometinib/defactinib in KRAS-mutant and KRAS-wild-type low-grade serous ovarian...

Key Takeaways

  • Verastem announced topline data from the RAMP 201 trial of avutometinib/defactinib in low-grade serous ovarian cancer.

  • It also initiated a rolling submission to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

GSK’s Nucala Set For Dupixent Face-Off After FDA COPD Nod

 
• By Kevin Grogan

The UK major's asthma drug gets a key expanded approval.

Merus Bispecific Impresses In Head And Neck Cancer

 
• By Andrew McConaghie

Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.

Boehringer’s CMO On How AI, Integrated Evidence Generation Underpin Its Ambitious Launch Plans

 
• By Alexandra Shimmings

The German company has big plans for the next five years or so. Scrip speaks to its chief medical officer Lykke Hinsch Gylvin about how it is using AI and other innovative approaches to make good on its ambitions.

Sanofi Makes Alzheimer’s Bet With Vigil Buy

 
• By Kevin Grogan

The French drugmaker is expanding its neurology activities with the $470m deal.

More from R&D

Sanofi Makes Alzheimer’s Bet With Vigil Buy

 
• By Kevin Grogan

The French drugmaker is expanding its neurology activities with the $470m deal.

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By Joseph Haas

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Merck KGaA Plans Phase III For Enpatoran After Mixed Phase II Lupus Data

 
• By Jessica Merrill

The Phase II study testing the novel TLR7/8 inhibitor met the primary endpoint in a cohort of patients with cutaneous lupus erythematosus and systemic lupus erythematosus with rash, but did not in patients with SLE.